<unk>  is mainly treated with immunosuppressants (80%), mostly cycles of IV corticosteroids (58%) in combination with IV immunoglobulins (IVIg−36%) and/or TPE (27%). Alternative successfully used, second-line treatments are Rituximab (22%) and Cyclophosphamide (12%), Azathioprine and Mycophenolat Mofetil. Sudden death is the most common outcome in nearly 34% of patients, irrespective of partial response to therapy. While complications from aspiration were the other common cause of death. Symptomatic treatment with CPAP in patients with OSA helps improve respiratory symptoms, while parasomnias and movement disorders (myoclonus, parkinsonism, and dystonia) did not respond when<unk> epileptic, dopaminergic, and<unk> -hyperkinetic drugs were administered.
Anti-IgLON5 disease
Hyper-IgM syndrome type 3
Hyper-IgM syndrome type 4
Hyper-IgM syndrome type 1
Hyper-IgM syndrome type 2
Hyper IgM syndrome
Hyper-IgM syndrome type 5
MOG antibody disease